Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon.

Szabolcs Koncz, Dóra Pothorszki, Noémi Papp, Donát Pál, György Bagdy

British Journal of Pharmacology June 1, 2026 DOI: 10.1111/bph.70399 (opens in new tab) via PubMed

Summary

AI-generated from the abstract

In rats, the (S)-enantiomer of ketamine (esketamine) produces a fourfold stronger wake-promoting effect and a twofold stronger increase in gamma brainwave power during wakefulness compared to the (R)-enantiomer (arketamine). Only esketamine enhances delta power during NREM sleep after gamma activity normalizes, a pattern called the gamma-delta shift. This shift, previously proposed as a marker of antidepressant activity for racemic ketamine, appears specific to esketamine. The findings help clarify which enantiomer drives the EEG changes and suggest that the gamma-delta shift may serve as a biomarker for antidepressant effects, relevant to treatment-resistant depression.

Study at a glance

Characteristics Experimental animal study Peer reviewed
Population Wistar rats
Interventions (S)-ketamine (R)-ketamine
Dose 7.5, 15 and 30 mg kg-1 for (S)-ketamine; 7.5, 15, 30 and 60 mg kg-1 for (R)-ketamine
Topics Esketamine Ketamine
Keywords Arousal Biomarker Qeeg
Citations 2
Key finding The gamma-delta shift phenomenon is specific to (S)-ketamine, not (R)-ketamine.

Abstract

Ketamine consists of two enantiomers, (R)-ketamine and (S)-ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)-enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)-ketamine. The quantitative electroencephalography (qEEG) gamma-enhancing effect of racemic ketamine has been reported before; moreover, a previous study has described a phenomenon that shows a temporal shift between the elevation of qEEG gamma and qEEG delta power, which we named as gamma-delta shift. It has been proposed as a marker of the antidepressant activity of racemic ketamine. To determine which enantiomer is responsible for these effects and in which sleep-wake states these changes occur, we compared the effects of the two enantiomers together with the separation of the different sleep-wake stages and examining dose dependency across a broad frequency spectrum. In Wistar rats, frontoparietal EEG and muscle activity were recorded following intraperitoneal administration of (S)-ketamine (7.5, 15 and 30 mg kg-1) or (R)-ketamine (7.5, 15, 30 and 60 mg kg-1) or vehicle at the beginning of the passive phase. Wake-inducing and NREM sleep-reducing effects of (S)-ketamine were fourfold stronger compared to (R)-ketamine. The gamma power increase induced by (S)-ketamine during wakefulness was twice as strong as that of (R)-ketamine. Additionally, once gamma activity normalized, only (S)-ketamine enhanced delta power during non-rapid eye movement (NREM) sleep and induced the gamma-delta shift. These findings indicate that the gamma-delta shift phenomenon is specific to (S)-ketamine.

Explore topics

Comments

No comments yet.

Log in to comment